期刊文献+

吡格列酮对糖尿病大鼠心肌缺血再灌注损伤的影响 被引量:1

Effects of pioglitazone on myocardial ischemia-reperfusion injury in diabetic rats
下载PDF
导出
摘要 目的观察糖尿病大鼠心肌缺血再灌注(MIR)时细胞间黏附分子-1(ICAM-1)和自由基代谢的变化及吡格列酮对其的影响,探讨糖尿病大鼠MIR损伤的机制。方法制作糖尿病大鼠模型,4周后作MIR模型。糖尿病大鼠30只分为假手术对照(sham)组,MIR组和吡格列酮组。免疫组织化学法检测心肌ICAM-1蛋白表达。检测血清、心肌组织超氧化物酶(SOD)、丙二醛(MDA)、谷胱甘肽-过氧化物酶(GSH-PX)及心肌线粒体Na+,K+-ATP酶、Mg2+-ATP酶、Ca2+-ATP酶活性。结果与sham组相比,MIR组心肌线粒体Na+,K+-ATP酶、Mg2+-ATP酶、Ca2+-ATP酶活性明显下降(P<0.05),血清SOD明显降低(P<0.01),心肌SOD和血清、心肌GSH-PX明显降低(P<0.05),血清、心肌MDA明显升高(P<0.05),心肌ICAM-1蛋白表达明显升高(P<0.01)。用吡格列酮4周后线粒体Na+,K+-ATP酶、Mg2+-ATP酶、Ca2+-ATP酶活性高于MIR组(P<0.05),血清、心肌SOD和GSH-PX水平高于MIR组(P<0.05),心肌MDA低于MIR组(P<0.01),心肌ICAM-1蛋白表达低于MIR组(P<0.05)。结论吡格列酮可减轻糖尿病心肌缺血再灌注损伤。 Objective To observe the effects of pioglitazone on the changes of the intercellular adhesion molecule-1 (ICAM-1) and free radicals in ischemia-reperfused myocardium(MIR) of diabetic rats, and investigate the reasons of myocardial ischemia-reperfusion injury in diabetic rats. Methods The diabetic rat model was established by streptozotocin injection to the abdominal cavity of Spraque- Dawlay rats. Four weeks later, the myocardial ischemic-reperfused models were established in anesthetic SD rats. Thirty SD rats were divided into three groups with 10 rats each (sham group,MIR group and pioglitazone group ). The ICAM-1 protein expressions were evaluated by immunocytochemistry. The contents of malondialdehyde(MDA) in serum and myocardial tissues were detected. The activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) in serum and myocardial tissues were measured. The activities of Mg^2+-ATPase, Ca^2+-ATPase and Na^+ ,K^+-ATPase in myocardial mitochondria were measured. Results Compared with sham group, the activities of Na^+ , K^+-ATPase, Mg^2+-ATPase, Ca^2+-ATPase in myocardial mitochondria were decreased significantly (P〈0. 05), the contents of MDA in serum and myocardium were increased significantly (P〈 0. 05) , the activities of GSH-PX in serum and myocardium were decreased significantly (P〈0. 05), the activities of SOD in serum and myocardium (P〈0. 01 and P〈0.05, respectively) were decreased significantly, the expression levels of ICAM-1 protein in myocardium were increased significantly in MIR group (P〈0. 01). Compared with MIR group, the activities of Na^+, K^+-ATPase, Mg^2+-ATPase, Ca^2+-ATPase in myocardial mitochondria were increased significantly (P〈0. 05), the contents of MDA in myocardium were decreased significantly (P〈 0. 01), the activities of SOD and GSH-PX in serum and myocardium were increased significantly (P〈 0. 05), the expression levels of ICAM-1 protein in myocardium were decreased significantly in pioglitazone group (P〈 0.05). Conclusions Pioglitazone could relieve myocardial ischemia- reperfusion injury induced by MIR in diabetic rats.
出处 《江苏医药》 CAS CSCD 北大核心 2008年第3期277-279,共3页 Jiangsu Medical Journal
关键词 吡格列酮 心肌缺血再灌注损伤 糖尿病 细胞间黏附分子-1 自由基 Piogtazone Myocardial ischemia-reperfusion injury Diabetes Intercellular adhesion molecule-1 Free radicals
  • 相关文献

参考文献5

  • 1Woodfield SL, Lundergan CF, Reiner JS, et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUATO-1 experience[J]. J Am Coll Cardiol, 1996,28(7) : 1661-1669.
  • 2Hattori Y, Matsuda N, Kimura J, et al. Diminished function and expression of the cardiac Na^+-Ca^2+ exchanger in diabetic rats: implication in Ca^2+ overload[J]. J Physiol, 2001, 527 (pt1) :85-94.
  • 3Roffaele M, Kathrine E, Rriccardo G, et al. Circulation adhesion molecules in humans role of hyperglycemia and hyperinsulin emial[J]. Circulation, 2000,101(19) : 2247-2251.
  • 4Yue TL, Chen J. In vivo myocardial protection from ischemi- a/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone [J ]. Circulation, 2001, 104 (21) : 2588-2594.
  • 5袁晓晨,刘乃丰,严俊峰,焦云根.糖基化终产物诱导血管平滑肌细胞增殖及药物的拮抗作用[J].江苏医药,2006,32(6):552-554. 被引量:1

二级参考文献7

  • 1Law RE,Goetze S,Xiaoping X,et al.Expression and function of PPARγ in rat and human vascular smooth muscle cells.Circulation,2000,101:1311-1320.
  • 2Aso Y,Inukai T,Tayama K,et al.Serum concentrations of advanced glycation end products are associated with the develop-ment of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes.Acta Diabetol,2000,37:87-92.
  • 3Yamamoto Y,Yamagishi S,Yonekuea H,et al.Roles of the AGERAGE system in vascular injury in diadetes.Ann N Y Acad Sci,2000,902:163-170.
  • 4Tuttle KR,Johnson EC,Cooney SK,et al.Amino acids injure mesangial cells by advanced glycation end products,oxidative stress,and protein kinase C.Kidney Int,2005,67:953-968.
  • 5Collins AR,Meehan WP,Kintscher U,et al.Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.Arterioscler Thromb Vasc Biol,2001,21:365-371.
  • 6Neve BP,Fruchart JC,Staels B.Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.Biochemical Pharmacology,2000,60:1245-1250.
  • 7Benson S,Wu J,Padmanabhan S,et al.Peroxisome proliferatoractivated receptor(PPAR)-gamma expression in human vascular smooth muscle ceils:inhibition of growth,migration,and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone.Am J Hypertens,2000,13:74-82.

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部